Eluxadoline
|
|
- CAS-Nr.
- 864821-90-9
- Englisch Name:
- Eluxadoline
- Synonyma:
- CS-2329;EOS-61916;Eluxadolin;Eluxadoline;API-Diarrhea;JNJ 27018966;The yi lu Lin;Eluxadoline 13CD4;Eluxadoline (Viberzi);Eluxadoline(JNJ 27018966)
- CBNumber:
- CB12723517
- Summenformel:
- C32H35N5O5
- Molgewicht:
- 569.65
- MOL-Datei:
- 864821-90-9.mol
|
Eluxadoline Eigenschaften
- Schmelzpunkt:
- >180°C (dec.)
- Siedepunkt:
- 834.2±65.0 °C(Predicted)
- Dichte
- 1.284±0.06 g/cm3(Predicted)
- storage temp.
- Refrigerator
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 4.01±0.10(Predicted)
- Farbe
- White to Off-White
- CAS Datenbank
- 864821-90-9
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
DEA Controlled Substances |
CSCN: 9725 CAS SCH: IV NARC: N |
|
|
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H361 |
Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. |
Reproduktionstoxizität |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
|
Sicherheit |
P201 |
Vor Gebrauch besondere Anweisungen einholen. |
P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
P281 |
Vorgeschriebene persönliche Schutzausrüstung verwenden. |
P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
P405 |
Unter Verschluss aufbewahren. |
P501 |
Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Eluxadoline Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Eluxadoline, originally developed
by Janssen and currently marketed by Allergan (formerly
Actavis), was approved in May 2015 by the FDA for the
treatment of diarrhea-predominant irritable bowel syndrome
(IBS-D). Eluxadoline, an orally dosed agent, employs a
unique mechanism for IBS-D treatment, as it functions
simultaneously as a μ- and κ-opioid receptor agonist and a δ-
opioid receptor antagonist, leading to a first-in-class therapy
for treatment of IBS-D. Specifically, in animal studies,
eluxadoline was found to interact with opioid receptors in the
gut, inhibiting neurogenically mediated secretion and reducing
intestinal contractility. Additionally, the treatment led to a
decrease in stress-induced acceleration of upper GI transit
without causing rebound constipation, earning its mark as
a first-line therapeutic treatment for IBS-D. In two phase III
clinical trials of over 2400 patients with IBS-D, patients taking
eluxadoline showed a greater improvement toward the end
point (≥30% improvement from their baseline IBS-D score on
at least 50% of days treated with eluxadoline) compared to
patients treated with placebo.
Verwenden
Eluxadoline is an orally-active drug used to reduce symptoms of irritable bowel syndrome such as diarrhea and abdominal pain.
Definition
ChEBI: An amino acid amide obtained by the formal condensation of the carboxy group of 4-carbamoyl-2,6-dimethyl-L-phenylalanine with the secondary amino group of 2-methoxy-5-({[(1S)-1-(4-phenylimidazol-2-yl)ethyl]amino}methyl)ben
oic acid. It has mixed opioid receptor activity and is used for treatment of irritable bowel syndrome with diarrhoea.
Eluxadoline Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Eluxadoline Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 168)Lieferanten
- JNJ 27018966
- Eluxadoline
- 5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic acid
- Eluxadolin
- API-Diarrhea
- Benzoic acid, 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxy-
- CS-2329
- Eluxadoline (Viberzi)
- EOS-61916
- 5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic acid
- Eluxadoline(JNJ 27018966)
- Eluxadoline 13CD4
- The yi lu Lin
- 864821-90-9
- API